A Compagnucci

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
  2. ncbi First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
    Abdel Babiker
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet Infect Dis 11:273-83. 2011
  3. ncbi Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome
    J-P Aboulker
    AIDS 18:237-45. 2004
  4. ncbi Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
    ..To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial...
  2. ncbi First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
    Abdel Babiker
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet Infect Dis 11:273-83. 2011
    ..We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line ART and viral load switch criteria in children...
  3. ncbi Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome
    J-P Aboulker
    AIDS 18:237-45. 2004
    ..However, a high rate of virological failure with emergence of genotypic resistance is of great concern. More palatable drug combinations for infants and closer drug monitoring are required...
  4. ncbi Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008
    ....